Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

Design considerations and best practices in clinical research

The increased focus on precision medicine in oncology and rare diseases has led to a marked increase of single-arm trials

- PMLiVE

Gilead and EVOQ Therapeutics partner in deal potentially worth over $650m

The companies will focus on developing therapies for rheumatoid arthritis and lupus

- PMLiVE

Valneva reports additional data for COVID-19 booster

VLA2001 was well tolerated in participants previously vaccinated with an mRNA vaccine

- PMLiVE

Novavax initiates phase 2 combination COVID-19/flu vaccine study

Initial results from the trial are expected towards the middle of the year

- PMLiVE

RQ Bio-discovered antibody enters clinic as part of AstraZeneca COVID-19 study

The trial will evaluate the UK-based biotech’s AZD3152 in combination with cilgavimab

- PMLiVE

Unlocking the potential of data sharing

The impact of privacy issues on clinical trials – how these issues limit studies and how they can be optimised

- PMLiVE

Pfizer announces positive phase 3 results for haemophilia B gene therapy

A one-off, intravenous dose of the therapy candidate reduced bleeding by 71%

- PMLiVE

Merck KGaA and Mersana partner in potential $830m deal

The companies will work together to develop novel antibody-drug conjugates

How to Increase Engagement During Virtual Events

Tip #6 - Individualizing a virtual event for your participants makes it more likely for them to attend and gain something valuable from the event. Learn how else you can...

Impetus Digital

How to Increase Engagement During Virtual Events

Tip #5 - Do you want to increase engagement during virtual events? To allow deep-dives into new data, discuss gaps/needs, or brainstorm new ideas, moderated small-group breakout sessions and workshops...

Impetus Digital

- PMLiVE

Sanofi and Innate Pharma expand cancer therapeutics collaboration

The partnership is aimed at exploring the potential of natural killer cells therapeutics in oncology

- PMLiVE

FDA approves Ferring’s Adstiladrin as first gene therapy for bladder cancer

Non-muscle-invasive bladder cancer represents around 75% of all new bladder cancer cases

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links